18:29 · 23 April 2020

BREAKING : Strong declines on Wall Street - Gilead drug rejected in phase I testing

In the last minutes we have been observing a strong declines on Wall Street. This is linked to recent rumors that a Gilead drug called Remdesivir, which showed the most promising initial results in the treatment of  coronavirus, was rejected in phase I tests. S&P 500 retreats from around 2830 points, below 2790 points. Gilead's stock is currently losing 2%. This information was provided by the Financial Times.
S&P 500 dropped sharpy lower after information regarding coronavirus drug hit the markets. Source: xStation5
16 June 2026, 18:53

Daily Summary - Oil Nearly Erases War Gains as Wall Street Pulls Back Ahead of Fed Decision (16.06.2026)

16 June 2026, 18:06

SpaceX surge continues, as oil falls below $80

16 June 2026, 14:56

US OPEN: SpaceX pushes Amazon off the TOP 5 podium. Wall Street awaits Warsh's debut

16 June 2026, 14:22

Nasdaq near record high 🔼 Is a double top forming?

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.